C-Met inhibitor D9 is a c-Met kinase inhibitor.

VEGFR-2/c-Met-IN-1 is a dual inhibitor targeting VEGFR-2 and c-Met with respective IC50 values of 138 nM and 74 nM, demonstrating antitumor activity [1].

c-Met-IN-15 exhibits antibacterial activity.

c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.

c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549, HT-29, SGC-7901, and MDA-MB-231, with IC50 values of 0.25, 0.36, 0.98, and 0.76 μM, respectively [1].

C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively. It is utilized in research pertaining to c-MET-driven cancers [1].

c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.

Gastrin hexapeptide is a hexapeptide from porcine antral mucosa.

c-Met-IN-13 is a potent inhibitor of c-Met (IC50: 2.43 nM). c-Met-IN-13 exhibits anti-proliferative effects in a concentration-dependent and time-dependent manner. c-Met-IN-13 exhibits significant cytotoxicity against cancer cells. c-Met-IN-13 has shown therapeutic potential against cancer.

c-Met-IN-12 is a selective, orally active type II c-Met kinase inhibitor (IC50: 10.6 nM). c-Met-IN-12 is a high inhibitor of AXL, Mer and TYRO3 kinases (>80% inhibition at 1 μM). c-Met-IN-12 can be used as a scaffold to further enhance kinase selectivity. c-Met-IN-12 exhibits anti-tumour activity.

c-Met/HDAC-IN-2 is a potent dual inhibitor of c-Met and HDAC, exhibiting IC50 values of 5.40 nM for c-Met and 18.49 nM for HDAC1, respectively. It demonstrates antiproliferative effects on various cancer cell lines, induces G2/M-phase arrest, and triggers apoptosis in HCT-116 cells, making it a promising candidate for anti-cancer resistance research.

c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).

SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor

c-Met/HDAC-IN-3, a dual inhibitor targeting both c-Met and HDAC, exhibits potent inhibitory activity with IC50 values of 12.50 nM for c-Met and 26.97 nM for HDAC1. It induces apoptosis and causes cell cycle arrest in the G2/M phase.

c-Met-IN-9 is a 4-phenoxypyridine derivative and a c-Met kinase inhibitor (IC50: 12 nM). c-Met-IN-9 induces apoptosis and shows antitumour effects.

BW 942C is a pentapeptide that is enkephalin-like.

c-Met-IN-14, a N-sulfonylamidine-based derivative, is a selective c-Met kinase inhibitor with an IC50 value of 2.89 nM. It exhibits anticancer properties by inhibiting c-Met phosphorylation and arresting the cell cycle at the G2/M phase. Additionally, c-Met-IN-14 promotes dose-dependent apoptosis in A549 cells.

c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]

c-Met-IN-10 is a potent c-Met kinase inhibitor (IC50: 16 nM). c-Met-IN-10 inhibits the activity of cancer cells A549, H460 and HT-29, and inhibits A549 cell movement by inhibiting HT-29 cell colony formation, which in turn induces apoptosis in HT-29 and A549 cells. c-Met-IN-10 can be used in anticancer studies. -Met-IN-10 is capable of being used in anticancer studies.

c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.

c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .

Antiproliferative Against-3 (comp 33) demonstrates significant activity against Hela (IC 50 = 0.21 µM), A549 (IC 50 = 0.39 µM), and MCF-7 (IC 50 = 0.33 µM) cell lines. Additionally, it induces apoptosis in a dose-dependent manner by arresting A549 cells in the G1 phase.

Tepotinib (EMD-1214063) is an inhibitor of MET tyrosine kinase with potential antineoplastic activity.

Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.

BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.

Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).

Capmatinib 2HCl (INC-280 2HCl) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.Capmatinib 2HCl exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10, 000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines. As a result, Capmatinib 2HCl potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro.

(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for FGFR, InsR, and EGFR. (Z)-Semaxinib is a quinolone derivative with potential antineoplastic activity.

Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).

MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an average inhibitory concentration (IC50) of 2.5 nM.

T-1840383 is an inhibitor of VEGF-induced VEGFR-2 phosphorylation and HGF-induced c-Met phosphorylation in vascular endothelial cells and cancer epithelial cells.

AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.

MK-8033 hydrochloride is an effective and orally active dual inhibitor of ATP competitive c-Met/Ron, with 1 nM for c-Met and 7nM for Ron IC50. MK-8033 hydrochloride has a high affinity for activated kinase conformation, and is suitable for the study of breast cancer, bladder cancer, and non-small cell lung cancer (NSCLC).

SOMCL-863 is a selective and orally bioavailable c-Met inhibitor. It shows antitumor activity both in vitro and in vivo.

Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.

MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.

JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM). The selectivity is higher 10-fold than MNK2, Fms and no inhibition of Met, c-Kit, PDGFRβ in A375 cell line.

Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.

Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.

Afatinib (BIBW 2992) is an irreversible inhibitor of EGFR family (EGFR-wt, EGFR-L858R, EGFR-L858R/T790M and HER2 with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM , respectively).

NVP-TAE 226 (TAE226) is an effective FAK inhibitor (IC50: 5.5 nM) and most effective to Pyk2(IC50: 3.5 nM); 10- to 100-fold less effective against IGF-1R, InsR, c-Met, and ALK.

Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF binding, receptor phosphorylation, and signal transduction.

Norleual TFA, an analog of angiotensin (Ang) IV, functions as a hepatocyte growth factor (HGF)/c-Met inhibitor, displaying a potent inhibition capability with an IC50 of 3 pM. Additionally, it acts as an AT4 receptor antagonist and demonstrates significant antiangiogenic activities [1].

Val-Cit-PAB-MMAE is a molecular entity designed to function as an antibody-drug conjugate (ADC) or as a component of bispecific antigen-binding molecules, specifically targeting the hepatocyte growth factor receptor known as c-Met (MET).

Damnacanthal possesses anti-cancer, immunomodulatory, antinociceptive and anti-inflammatory actions, it can treat or prevent hepatocellular carcinoma through its inhibitory effects on the HGF/c-Met axis.

MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.

Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.

MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).

Val-Cit-amide-Cbz-N(Me)-Maytansine is a molecule that functions both as an antibody and a bispecific antigen-binding entity, targeting the hepatocyte growth factor receptor c-Met (MET), and is used in the formulation of antibody-drug conjugates (ADCs) [1].

1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration of cancer cells. This compound is applicable in researching gastric, liver, and vascular tumors [1].

(S)-crizotinib (ent-crizotinib) （IC50 of 72 nM）, an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.

Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)

Crizotinib, an orally bioavailable agent, belongs to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity.